Format

Send to

Choose Destination
Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3.

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.

Kerdivel G1,2,3,4,5, Chesnais V1,2,3,4,6, Becht E4,7,8, Toma A9, Cagnard N10, Dumont F1,2,3,4,11, Rousseau A12, Fenaux P13, Chevret S14, Chapuis N1,2,3,4,6,12, Boeva V1,2,3,4,5, Fridman WH4,7, Fontenay M1,2,3,4,6,12, Kosmider O1,2,3,4,6,12.

Author information

1
Institut Cochin, Department Development, Reproduction, Cancer, Paris, France.
2
Institut National de la Santé et de la recherche médicale INSERM U1016, Paris, France.
3
Centre National de la recherche scientifique CNRS UMR8104, Paris, France.
4
Université Paris Descartes, Paris, France.
5
Team Computational (Epi-)Genetics of Cancer, Paris, France.
6
Team Normal and pathological hematopoiesis labeled Ligue nationale contre le cancer, Paris, France.
7
INSERM UMR_S1138, Cancer, Immune controls and Escape, Cordeliers Research Center, Paris, France.
8
Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
9
Assistance Publique-Hôpitaux de Paris, Service d'hématologie clinique et Thérapie Cellulaire, Hôpital Henri-Mondor, Créteil, France.
10
Plateforme Paris Descartes de Bioinformatique, Université Paris Descartes, Paris, France.
11
Plateforme de Génomique, Institut Cochin, Paris, France.
12
Assistance Publique-Hôpitaux de Paris, Service d'hématologie biologique, Hôpital Cochin, Paris, France.
13
Assistance Publique-Hôpitaux de Paris, Service d'hématologie senior, Hôpital Saint-Louis, Paris, France.
14
Assistance Publique-Hôpitaux de Paris, Laboratoire de Biostatistiques et Epidémiologie clinique INSERM UMR-S 717, Hôpital Saint-Louis, Paris, France.
PMID:
28972593
DOI:
10.1038/leu.2017.305
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center